RPTX insider trading
NasdaqGS HealthcareRepare Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Repare Therapeutics Inc.
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.
Company website: www.reparerx.com
RPTX insider activity at a glance
FilingIQ has scored 653 insider transactions for RPTX since Jun 23, 2020. The most recent filing in our index is dated Jan 28, 2026.
Across the full history, 46 open-market purchases
and 232 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RPTX insider trades is 59.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RPTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RPTX?
- FilingIQ tracks 653 Form 4 insider transactions for RPTX (Repare Therapeutics Inc.), covering filings from Jun 23, 2020 onwards. 0 of those were filed in the last 90 days.
- Are RPTX insiders net buyers or net sellers?
- Across the full Form 4 history for RPTX, 46 transactions (7%) were open-market purchases and 232 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RPTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RPTX in?
- Repare Therapeutics Inc. (RPTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $114.24M.
Methodology & sources
Every RPTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.